Meros Investment Management LP Invests $6.18 Million in Simulations Plus, Inc. $SLP

Meros Investment Management LP purchased a new position in shares of Simulations Plus, Inc. (NASDAQ:SLP) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 339,242 shares of the technology company’s stock, valued at approximately $6,184,000. Simulations Plus makes up approximately 2.5% of Meros Investment Management LP’s holdings, making the stock its 17th biggest holding.

A number of other hedge funds and other institutional investors have also made changes to their positions in SLP. First Eagle Investment Management LLC grew its position in shares of Simulations Plus by 1,898.1% during the 4th quarter. First Eagle Investment Management LLC now owns 457,155 shares of the technology company’s stock worth $8,334,000 after buying an additional 434,275 shares in the last quarter. First Light Asset Management LLC lifted its stake in shares of Simulations Plus by 115.0% during the 3rd quarter. First Light Asset Management LLC now owns 767,760 shares of the technology company’s stock worth $11,570,000 after purchasing an additional 410,603 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of Simulations Plus by 127.5% during the 4th quarter. Marshall Wace LLP now owns 569,783 shares of the technology company’s stock worth $10,387,000 after purchasing an additional 319,301 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Simulations Plus by 278.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 427,865 shares of the technology company’s stock worth $7,800,000 after purchasing an additional 314,844 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its stake in shares of Simulations Plus by 522.1% during the 3rd quarter. Squarepoint Ops LLC now owns 220,103 shares of the technology company’s stock worth $3,317,000 after purchasing an additional 184,725 shares during the last quarter. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Price Performance

Shares of NASDAQ SLP opened at $16.37 on Tuesday. The stock has a market capitalization of $330.67 million, a P/E ratio of -5.23 and a beta of 1.32. Simulations Plus, Inc. has a 1-year low of $11.09 and a 1-year high of $21.01. The business has a fifty day moving average price of $14.88 and a 200 day moving average price of $15.56.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Thursday, April 9th. The technology company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.08. Simulations Plus had a positive return on equity of 16.21% and a negative net margin of 77.96%.The company had revenue of $24.29 million during the quarter, compared to analysts’ expectations of $21.66 million. As a group, equities research analysts anticipate that Simulations Plus, Inc. will post 0.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on SLP. Weiss Ratings upgraded Simulations Plus from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, June 5th. TD Cowen decreased their price objective on Simulations Plus from $19.00 to $16.00 and set a “hold” rating for the company in a research note on Friday, April 10th. Finally, Wall Street Zen cut Simulations Plus from a “buy” rating to a “hold” rating in a research note on Saturday. Two investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $21.50.

Simulations Plus Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.